Omer Sagcan, MD
Hospitalist · Syracuse, NYNPI 1831388743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Pfizer at 28.2% of the total. Reporting peaked in 2023 at $796 and has fallen 52.2% since, to $380 in 2025. Among hospitalist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$770
- E.r. Squibb & Sons, L.L.C.$608
- Johnson & Johnson$602
- AbbVie$277
- Welch Allyn$200
- Novartis$148
- plus $130 from 3 others
What the payments were for
- Speaking & faculty fees$2007%
- Food & beverage$2,53493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 42 | $770 |
| E.r. Squibb & Sons, L.L.C. | 11 | $608 |
| Johnson & Johnson | 31 | $602 |
| AbbVie(2 entities) | 11 | $277 |
| Welch Allyn | 2 | $200 |
| Novartis | 7 | $148 |
| AstraZeneca | 3 | $52 |
| Boehringer Ingelheim | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,734 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CefuroximeCefuroxime Axetil | 19 | $135 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $103 |
| Oxycodone Hcl | 16 | $82 |
| Prednisone | 21 | $64 |
| Amlodipine Besylate | 18 | $50 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Syracuse
- Ali KhanSyracuse$6K
- Gagan Jot SinghSyracuse$6K
- Hammad RahmanSyracuse$5K
- Mostafa VasighSyracuse$5K
- Manika SuryadevaraSyracuse$4K
- Nelson Chan-HungRochester$445K
- Saquib RahimFlushing$239K
- Zainab Mogul-AshrafMiddletown$190K
- Salman AzimRochester$88K
- Usman SiddiquiNyack$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.